Page last updated: 2024-09-04

moxifloxacin and Bacterial Disease

moxifloxacin has been researched along with Bacterial Disease in 73 studies

Research

Studies (73)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	2 (2.74)	18.2507
2000's	40 (54.79)	29.6817
2010's	27 (36.99)	24.3611
2020's	4 (5.48)	2.80

Authors

Authors	Studies
Baek, SY; Chae, SE; Cho, YL; Jeong, JW; Jung, SJ; Kim, YZ; Kwak, JH; Lee, HH; Lee, HS; Park, TK; Woo, SH	1
Chen, L; Franzblau, SG; Liu, X; Lu, X; Wan, B; You, Q; Zhou, C	1
Lynch, AS; Ma, Z	1
Betson, M; Bingham, M; Doyle, P; Hallworth, S; Harvey, R; Huxley, A; Kirk, R; Moat, J; Nelson, G; Pesnot, T; Tait, M	1
Cobo, F; Navarro-Marí, JM; Sadyrbaeva-Dolgova, S	1
Chuck, RS; Jung, MY; Kim, DJ; Kim, M; Pak, HJ; Park, CY; Park, JH	1
Li, HQ; Ning, W; Wang, JX; Zhang, F	1
Abousoud, O; Dagli, M; Gade, T; Hunt, S; Mondschein, J; Nadolski, GJ; Parikh, RS; Shamimi-Noori, S; Soulen, MC; Stavropoulos, SW; Sudheendra, D	1
Dixit, A; Jones, S; Karandikar, MV; Nakamura, MM	1
Chatzika, K; Kioumis, I; Kontou, P; Manika, K; Pitsiou, G; Sionidou, M; Zarogoulidis, P	1
Gao, F; Huang, G; Kong, F; Xiao, J; Ye, L	1
Keating, KN; Lloyd, A; Nafees, B; Piccirillo, J; Quadri, N; Wild, D	1
Borggren, M; Nygart, JF; Nygart, VA; Tvede, M	1
Edzhe, MA; Hon, EM; Korostelev, SA; Miroshnichenko, NA; Ovchinnikov, AY	1
Adelglass, J; Benson, A; Johnson, P; Keating, K; Pertel, P; Rankin, B; Sterling, R	1
Hampel, B; Lippert, H; Muehlhofer, E; Reimnitz, P; Weiss, G	1
Carmona, IT; Diz Dios, P; Limeres Posse, J; Núñez Otero, V	1
Encke, J; Gutt, C; Hoppe-Tichy, T; Köninger, J; Ober, MC; Schunter, O; Sonntag, HG; Swoboda, S; Weigand, MA	1
Hsueh, PR; Huang, YT; Liao, CH; Liu, CY; Lu, CL	1
Goudah, A; Hasabelnaby, S	1
Hu, B; Jiang, X; Liang, C; Ruan, B; Wang, H; Wang, J; Xiao, G; Xiao, S; Ye, Q; Zhai, L; Zhou, B	1
Desrosiers, M; Hadley, JA; Haverstock, D; Herman-Gnjidic, Z; Mösges, R; van Veenhuyzen, D	1
Cheadle, W; Lee, JT; Napolitano, LM; Nichols, RL	1
Czaika, V; Drewelow, B; Gussmann, A; Klar, E; Koch, H; Kujath, P; Lobmann, R; Luebbert, C; Majcher-Peszynska, J; Mundkowski, RG; Ruf, BR; Sass, M; Schareck, W; Schipper, S	1
Wintenberger, C	1
Bertino, JS; Jones, RN; Segreti, J	1
El-Adly, AA; El-Laithy, HM; Nesseem, DI; Shoukry, M	1
Alder, J; Anzueto, A; Arvis, P; Haverstock, D; Miravitlles, M; Sethi, S; Trajanovic, M; Wilson, R	1
Arenz, D; Böll, B; Bredenfeld, H; Chemnitz, J; Cornely, OA; Cremer, B; Hallek, M; Kaul, I; Klein, F; Mahne, M; Moritz, G; Scheid, C; Vehreschild, JJ; Vehreschild, MJ; Wassmer, G	1
Deng, X; Liu, RL; Mu, YP; Wang, LQ; Wang, Y; Wei, MD; Zhu, N	1
Balzer, L; Böger, RH; Cachovan, G; Giersdorf, I; Haddad, M; Hallier, O; Platzer, U; Sobottka, I; Streichert, T; Wegscheider, K	1
Acharya, NR; Bharathi, MJ; Cevallos, V; Glidden, DV; Lalitha, P; Lietman, TM; Manikandan, P; McLeod, SD; Oldenburg, CE; Rajaraman, R; Ravindran, M; Ray, KJ; Srinivasan, M; Toutain-Kidd, CM; Zegans, ME	1
Boersma, WG	1
Macklin-Doherty, A; Wilson, R	1
Alder, J; Arvis, P; Dryden, M; Gyssens, IC; Kujath, P; Nathwani, D; Reimnitz, P; Schaper, NC	1
Behra-Miellet, J; Dubreuil, L; Jumas-Bilak, E	1
Arvis, P; Klossek, JM; Leberre, MA; Nikolaidis, P; Siegert, R	1
Block, N; Drewelow, B; Kuhn-Thiel, A; Mundkowski, RG; Park, S; Wacke, R	1
Karpov, OI; Strekachev, AIu; Zaĭtsev, AA	1
Frisbee-Hume, S; Ho, DH; LeBlanc, B; Rolston, KV; Streeter, H	1
Braun, J; Dirnagl, U; Halle, E; Megow, D; Meisel, A; Meisel, C; Prass, K; Victorov, I; Volk, HD; Wolf, T	1
Cambria, RA; Edmiston, CE; Krepel, CJ; Nakeeb, A; Seabrook, GR; Somberg, LR; Towne, JB	1
Bassaris, H; Gogos, CA; Starakis, I	1
Mah, FS	1
Dmitrieva, NV; Minenko, SV; Ptushkin, VV; Sokolova, EN; Zhukov, NV	1
Ahmed, S; Fuhrmann, V; Jaeger, W; Schenk, P; Thalhammer, F	1
Ferguson, BJ; Guzzetta, RV; Hadley, JA; Spector, SL	1
Ardanza-Trevijano, B; Canut, A; Isla, A; Labora, A; Pedraz, JL; Rodríguez-Gascón, A; Solinís, MA	1
Sethi, S	1
Anon, JB	1
Almassi, GH; Brown, KR; Edmiston, CE; Kehl, KS; Krepel, CJ; Lewis, BD; Loehrl, TA; Seabrook, GR; Smith, TL; Somberg, LB; Towne, JB	1
Blatun, LA; Svetukhin, AM; Ukhin, SA	1
Kolokotronis, AE; Stefanopoulos, PK	1
Choudhri, S; Herrington, J; Malangoni, MA; Pertel, P; Song, J	1
Catero, M	1
Choudhri, S; Giordano, P; Lipsky, BA; Song, J	1
Iannini, PB	1
Iakovlev, VP; Iakovlev, VS	1
Arnold, G; Bereswill, S; Dirnagl, U; Drenckhahn, C; Göbel, U; Göhler, J; Halle, E; Harms, H; Klehmet, J; Meisel, A; Meisel, C; Prass, K; Rogge, W; Volk, HD; Wernecke, KD; Wolf, T	1
Aldridge, KE; Ashcraft, DS	1
Balfour, JA; Wiseman, LR	1
Aneiro, L; Chodosh, S; Church, D; DeAbate, CA; Haverstock, D	1
Ackermann, G; Claros, MC; Goldstein, EJ; Pless, B; Rodloff, AC; Schaumann, R	1
Bagger-Sjöbäck, D; Gehanno, P; Hampel, B; Ibanez, JM; Nikolaidis, P; Siegert, R; Sommerauer, B	1
Church, D; DeAbate, CA; Heyd, A; Mathew, CP; Warner, JH	1
Barrett, JF	1
Culley, CM; Edwards, B; Klutman, N; Lacy, MK	1
Chang, SC; Chen, YC; Luh, KT; Sheng, WH; Wang, JT	1
Betlejewska, K; Hryniewicz, W	1

Reviews

18 review(s) available for moxifloxacin and Bacterial Disease

Article	Year
[15-year experience of moxifloxacin in the treatment of patients with bacterial rhinosinusitis]. Vestnik otorinolaringologii, 2015, Volume: 80, Issue:3 Topics: Acute Disease; Anti-Bacterial Agents; Bacterial Infections; Fluoroquinolones; Humans; Moxifloxacin; Rhinitis; Russia; Sinusitis; Treatment Outcome	2015
Efficacy of fluoroquinolones against pathogenic oral bacteria. Mini reviews in medicinal chemistry, 2009, Volume: 9, Issue:10 Topics: Aza Compounds; Bacteria; Bacterial Infections; Ciprofloxacin; Fluoroquinolones; Humans; Levofloxacin; Mouth Diseases; Moxifloxacin; Ofloxacin; Oral Medicine; Quinolines	2009
Clinical update on the use of moxifloxacin in the treatment of community-acquired complicated intraabdominal infections. Surgical infections, 2010, Volume: 11, Issue:5 Topics: Anti-Bacterial Agents; Aza Compounds; Bacterial Infections; Community-Acquired Infections; Fluoroquinolones; Humans; Moxifloxacin; Peritonitis; Quinolines	2010
Challenges in assessing microbial susceptibility and predicting clinical response to newer-generation fluoroquinolones. Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics, 2012, Volume: 28, Issue:1 Topics: Administration, Ophthalmic; Animals; Anti-Bacterial Agents; Aza Compounds; Azepines; Bacteria; Bacterial Infections; Drug Resistance, Bacterial; Fluoroquinolones; Gatifloxacin; Humans; Microbial Sensitivity Tests; Models, Biological; Moxifloxacin; Quinolines	2012
Moxifloxacin monotherapy for treatment of complicated intra-abdominal infections: a meta-analysis of randomised controlled trials. International journal of clinical practice, 2012, Volume: 66, Issue:2 Topics: Adult; Aged; Anti-Infective Agents; Aza Compounds; Bacterial Infections; Fluoroquinolones; Humans; Intraabdominal Infections; Middle Aged; Moxifloxacin; Quinolines; Randomized Controlled Trials as Topic; Treatment Outcome	2012
The use of moxifloxacin for acute exacerbations of chronic obstructive pulmonary disease and chronic bronchitis. Expert review of respiratory medicine, 2012, Volume: 6, Issue:5 Topics: Acute Disease; Anti-Infective Agents; Aza Compounds; Bacterial Infections; Bronchitis; Chronic Disease; Fluoroquinolones; Humans; Moxifloxacin; Pulmonary Disease, Chronic Obstructive; Quinolines	2012
[New approaches to antibacterial therapy of infections in the surgical practice]. Antibiotiki i khimioterapiia = Antibiotics and chemoterapy [sic], 2003, Volume: 48, Issue:5 Topics: Abdominal Abscess; Aza Compounds; Bacterial Infections; beta-Lactams; Community-Acquired Infections; Cross Infection; Ertapenem; Fluoroquinolones; Humans; Lactams; Moxifloxacin; Quinolines; Randomized Controlled Trials as Topic; Surgical Wound Infection	2003
Fourth-generation fluoroquinolones: new topical agents in the war on ocular bacterial infections. Current opinion in ophthalmology, 2004, Volume: 15, Issue:4 Topics: Administration, Topical; Aza Compounds; Bacterial Infections; Eye Infections; Fluoroquinolones; Gatifloxacin; Humans; Moxifloxacin; Quinolines	2004
[Pharmacokinetic/pharmacodynamic analysis of antibiotic therapy in dentistry and stomatology]. Enfermedades infecciosas y microbiologia clinica, 2005, Volume: 23, Issue:3 Topics: Algorithms; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Area Under Curve; Aza Compounds; Bacterial Infections; Clindamycin; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Therapy, Combination; Fluoroquinolones; Fusobacterium nucleatum; Humans; Microbial Sensitivity Tests; Mouth Diseases; Moxifloxacin; Peptostreptococcus; Periodontitis; Porphyromonas gingivalis; Prevotella intermedia; Quinolines; Time Factors; Viridans Streptococci	2005
Moxifloxacin for the treatment of acute exacerbations of chronic obstructive pulmonary disease. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2005, Jul-15, Volume: 41 Suppl 2 Topics: Adult; Aza Compounds; Bacterial Infections; Chlamydophila pneumoniae; Controlled Clinical Trials as Topic; Fluoroquinolones; Humans; Moxifloxacin; Pulmonary Disease, Chronic Obstructive; Quinolines	2005
Current management of acute bacterial rhinosinusitis and the role of moxifloxacin. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2005, Jul-15, Volume: 41 Suppl 2 Topics: Anti-Bacterial Agents; Aza Compounds; Bacterial Infections; Clinical Trials as Topic; Drug Resistance, Microbial; Fluoroquinolones; Gatifloxacin; Haemophilus influenzae; Humans; Levofloxacin; Meta-Analysis as Topic; Moxifloxacin; Ofloxacin; Practice Guidelines as Topic; Quinolines; Rhinitis; Sinusitis; Streptococcus pneumoniae	2005
[Moxifloxacin, a novel extended spectrum fluoroquinolone in the treatment of severe infectious inflammatory diseases]. Antibiotiki i khimioterapiia = Antibiotics and chemoterapy [sic], 2005, Volume: 50, Issue:2-3 Topics: Anti-Bacterial Agents; Aza Compounds; Bacteria; Bacterial Infections; Fluoroquinolones; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Moxifloxacin; Quinolines; Spores, Bacterial; Surgical Wound Infection	2005
Dysglycemia and fluoroquinolones: are you putting patients at risk? The Journal of family practice, 2007, Volume: 56, Issue:2 Topics: Adolescent; Adult; Aza Compounds; Bacterial Infections; Blood Glucose; Ciprofloxacin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Approval; Evidence-Based Medicine; Family Practice; Female; Fluoroquinolones; Gatifloxacin; Humans; Hyperglycemia; Hypoglycemia; Incidence; Male; Middle Aged; Moxifloxacin; Ofloxacin; Quinolines; Randomized Controlled Trials as Topic; Risk Assessment; United States; United States Food and Drug Administration	2007
The safety profile of moxifloxacin and other fluoroquinolones in special patient populations. Current medical research and opinion, 2007, Volume: 23, Issue:6 Topics: Aged; Anti-Bacterial Agents; Aza Compounds; Bacterial Infections; Cardiovascular Diseases; Fluoroquinolones; Glucose; Homeostasis; Humans; Kidney Diseases; Liver Diseases; Metabolic Diseases; Moxifloxacin; Population Groups; Quinolines; Risk Factors	2007
[Investigation of moxifloxacin, a new antimicrobial of the fluoroquinolone group in Russia]. Antibiotiki i khimioterapiia = Antibiotics and chemoterapy [sic], 2007, Volume: 52, Issue:6 Topics: Anti-Infective Agents; Aza Compounds; Bacterial Infections; Fluoroquinolones; Humans; Hydrocarbons, Fluorinated; Moxifloxacin; Quinolines; Russia	2007
Moxifloxacin. Drugs, 1999, Volume: 57, Issue:3 Topics: Anti-Infective Agents; Area Under Curve; Aza Compounds; Bacterial Infections; Ciprofloxacin; Drug Interactions; Fluoroquinolones; Half-Life; Humans; Metabolic Clearance Rate; Microbial Sensitivity Tests; Moxifloxacin; Quinolines	1999
Moxifloxacin Bayer. Current opinion in investigational drugs (London, England : 2000), 2000, Volume: 1, Issue:1 Topics: Animals; Anti-Infective Agents; Aza Compounds; Bacteria; Bacterial Infections; Contraindications; Fluoroquinolones; Humans; Moxifloxacin; Quinolines; Structure-Activity Relationship	2000
Moxifloxacin: clinical efficacy and safety. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2001, Mar-01, Volume: 58, Issue:5 Topics: Anti-Infective Agents; Aza Compounds; Bacterial Infections; Fluoroquinolones; Humans; Moxifloxacin; Quinolines	2001

Trials

21 trial(s) available for moxifloxacin and Bacterial Disease

Article	Year
Systemic inflammation and the effects of short-term antibiotic treatment for PPM positive patients with stable COPD. International journal of chronic obstructive pulmonary disease, 2019, Volume: 14 Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Bacteria; Bacterial Infections; China; Disease Progression; Drug Administration Schedule; Female; Humans; Inflammation Mediators; Male; Middle Aged; Moxifloxacin; Pulmonary Disease, Chronic Obstructive; Respiratory Tract Infections; Risk Factors; Sputum; Time Factors; Treatment Outcome	2019
Psychometric evaluation of the Sinonasal Outcome Test-16 and activity impairment assessment in acute bacterial sinusitis. Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery, 2013, Volume: 149, Issue:1 Topics: Activities of Daily Living; Adult; Anti-Bacterial Agents; Aza Compounds; Bacterial Infections; Cohort Studies; Disability Evaluation; Female; Fluoroquinolones; Humans; Male; Middle Aged; Moxifloxacin; Outcome Assessment, Health Care; Psychometrics; Quinolines; Recovery of Function; Reproducibility of Results; Self Report; Sinusitis	2013
Acute bacterial maxillary sinusitis: time to symptom resolution and return to normal activities with moxifloxacin. International journal of clinical practice, 2008, Volume: 62, Issue:9 Topics: Acute Disease; Adolescent; Adult; Aged; Anti-Infective Agents; Aza Compounds; Bacterial Infections; Female; Fluoroquinolones; Humans; Male; Maxillary Sinusitis; Middle Aged; Moxifloxacin; Prospective Studies; Quinolines; Treatment Outcome; Young Adult	2008
Moxifloxacin for the treatment of patients with complicated intra-abdominal infections (the AIDA Study). Journal of chemotherapy (Florence, Italy), 2009, Volume: 21, Issue:2 Topics: Abdominal Abscess; Administration, Oral; Adult; Aged; Amoxicillin-Potassium Clavulanate Combination; Anti-Infective Agents; Appendicitis; Aza Compounds; Bacterial Infections; Ceftriaxone; Drug Therapy, Combination; Female; Fluoroquinolones; Gastrointestinal Diseases; Humans; Infusions, Intravenous; Intestinal Perforation; Male; Metronidazole; Microbial Sensitivity Tests; Middle Aged; Moxifloxacin; Peritonitis; Prospective Studies; Quinolines	2009
Moxifloxacin in the treatment of acute bacterial rhinosinusitis: results of a multicenter, non-interventional study. Acta oto-laryngologica, 2010, Volume: 130, Issue:9 Topics: Adolescent; Adult; Aged; Anti-Infective Agents; Aza Compounds; Bacterial Infections; Female; Fluoroquinolones; Humans; Male; Middle Aged; Moxifloxacin; Product Surveillance, Postmarketing; Prospective Studies; Quinolines; Rhinitis; Sinusitis; Treatment Outcome; Young Adult	2010
Moxifloxacin five-day therapy versus placebo in acute bacterial rhinosinusitis. The Laryngoscope, 2010, Volume: 120, Issue:5 Topics: Administration, Oral; Adult; Anti-Infective Agents; Aza Compounds; Bacterial Infections; Double-Blind Method; Drug Administration Schedule; Female; Fluoroquinolones; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Moxifloxacin; Patient Dropouts; Quinolines; Rhinitis; Sinusitis; Treatment Outcome	2010
Pharmacokinetics and penetration of moxifloxacin into infected diabetic foot tissue in a large diabetic patient cohort. European journal of clinical pharmacology, 2011, Volume: 67, Issue:2 Topics: Aged; Aged, 80 and over; Anti-Infective Agents; Aza Compounds; Bacterial Infections; Cohort Studies; Diabetes Mellitus, Type 2; Diabetic Foot; Female; Fluoroquinolones; Humans; Male; Middle Aged; Moxifloxacin; Prospective Studies; Quinolines	2011
Moxifloxacin versus amoxicillin/clavulanic acid in outpatient acute exacerbations of COPD: MAESTRAL results. The European respiratory journal, 2012, Volume: 40, Issue:1 Topics: Aged; Aged, 80 and over; Ambulatory Care; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Aza Compounds; Bacterial Infections; Double-Blind Method; Female; Fluoroquinolones; Humans; Male; Middle Aged; Moxifloxacin; Prospective Studies; Pulmonary Disease, Chronic Obstructive; Quinolines; Treatment Outcome	2012
Efficacy and safety of moxifloxacin as antibacterial prophylaxis for patients receiving autologous haematopoietic stem cell transplantation: a randomised trial. International journal of antimicrobial agents, 2012, Volume: 39, Issue:2 Topics: Adult; Aged; Anti-Bacterial Agents; Antibiotic Prophylaxis; Antineoplastic Agents; Aza Compounds; Bacteremia; Bacterial Infections; Double-Blind Method; Female; Fluoroquinolones; Humans; Male; Middle Aged; Moxifloxacin; Neutropenia; Pilot Projects; Placebos; Prospective Studies; Quinolines; Stem Cell Transplantation; Treatment Outcome	2012
Microbiological analysis of a prospective, randomized, double-blind trial comparing moxifloxacin and clindamycin in the treatment of odontogenic infiltrates and abscesses. Antimicrobial agents and chemotherapy, 2012, Volume: 56, Issue:5 Topics: Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Aza Compounds; Bacteria, Aerobic; Bacteria, Anaerobic; Bacterial Infections; Clindamycin; Culture Media; Double-Blind Method; Female; Fluoroquinolones; Germany; Humans; Male; Microbial Sensitivity Tests; Moxifloxacin; Outpatients; Penicillins; Periodontal Abscess; Prospective Studies; Quinolines	2012
Efficacy and safety of IV/PO moxifloxacin and IV piperacillin/tazobactam followed by PO amoxicillin/clavulanic acid in the treatment of diabetic foot infections: results of the RELIEF study. Infection, 2013, Volume: 41, Issue:1 Topics: Administration, Intravenous; Administration, Oral; Aged; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Aza Compounds; Bacteria; Bacterial Infections; Diabetic Foot; Female; Fluoroquinolones; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Moxifloxacin; Penicillanic Acid; Piperacillin; Quinolines; Tazobactam; Treatment Outcome	2013
Comparison of the efficacy and safety of moxifloxacin and trovafloxacin for the treatment of acute, bacterial maxillary sinusitis in adults. The Journal of laryngology and otology, 2003, Volume: 117, Issue:1 Topics: Acute Disease; Adult; Anti-Infective Agents; Aza Compounds; Bacterial Infections; Dose-Response Relationship, Drug; Double-Blind Method; Female; Fluoroquinolones; Humans; Male; Maxillary Sinusitis; Microbial Sensitivity Tests; Middle Aged; Moxifloxacin; Naphthyridines; Prospective Studies; Quinolines; Treatment Outcome	2003
Five-day moxifloxacin therapy compared with 7-day co-amoxiclav therapy for the treatment of acute exacerbation of chronic bronchitis. International journal of antimicrobial agents, 2004, Volume: 23, Issue:2 Topics: Adult; Aged; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Aza Compounds; Bacteria; Bacterial Infections; Bronchitis, Chronic; Drug Therapy, Combination; Female; Fluoroquinolones; Humans; Male; Middle Aged; Moxifloxacin; Quinolines; Sputum; Treatment Outcome	2004
[Efficacy of moxifloxacin (Avelox) in prophylaxis of infection in patients with profound neutropenia]. Antibiotiki i khimioterapiia = Antibiotics and chemoterapy [sic], 2004, Volume: 49, Issue:3 Topics: Administration, Oral; Adolescent; Adult; Anti-Bacterial Agents; Antineoplastic Agents; Aza Compounds; Bacterial Infections; Female; Fluoroquinolones; Humans; Male; Middle Aged; Moxifloxacin; Neutropenia; Quinolines	2004
Efficacy and safety of oral telithromycin once daily for 5 days versus moxifloxacin once daily for 10 days in the treatment of acute bacterial rhinosinusitis. Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery, 2004, Volume: 131, Issue:3 Topics: Acute Disease; Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Aza Compounds; Bacterial Infections; Double-Blind Method; Drug Administration Schedule; Female; Fluoroquinolones; Humans; Ketolides; Macrolides; Male; Middle Aged; Moxifloxacin; Prospective Studies; Quinolines; Rhinitis; Sinusitis; Time Factors	2004
Randomized controlled trial of moxifloxacin compared with piperacillin-tazobactam and amoxicillin-clavulanate for the treatment of complicated intra-abdominal infections. Annals of surgery, 2006, Volume: 244, Issue:2 Topics: Abdominal Abscess; Administration, Oral; Adult; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Appendicitis; Aza Compounds; Bacterial Infections; Cross Infection; Double-Blind Method; Female; Fluoroquinolones; Gram-Negative Bacterial Infections; Gram-Positive Bacterial Infections; Humans; Injections, Intravenous; Intestinal Perforation; Male; Middle Aged; Moxifloxacin; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Prospective Studies; Quinolines; Safety; Stomach Rupture; Treatment Outcome	2006
Treating diabetic foot infections with sequential intravenous to oral moxifloxacin compared with piperacillin-tazobactam/amoxicillin-clavulanate. The Journal of antimicrobial chemotherapy, 2007, Volume: 60, Issue:2 Topics: Aged; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Aza Compounds; Bacterial Infections; Databases, Factual; Diabetic Foot; Double-Blind Method; Female; Fluoroquinolones; Humans; Male; Moxifloxacin; Penicillanic Acid; Piperacillin; Quinolines; Tazobactam	2007
Preventive antibacterial therapy in acute ischemic stroke: a randomized controlled trial. PloS one, 2008, May-14, Volume: 3, Issue:5 Topics: Aged; Anti-Bacterial Agents; Aza Compounds; Bacterial Infections; Body Temperature; Brain Ischemia; C-Reactive Protein; Double-Blind Method; Drug Resistance, Bacterial; Female; Fluoroquinolones; Humans; Male; Moxifloxacin; Placebos; Quinolines; Respiration, Artificial; Risk Factors; Stroke; Survival Analysis	2008
Short-course moxifloxacin therapy for treatment of acute bacterial exacerbations of chronic bronchitis. The Bronchitis Study Group. Respiratory medicine, 2000, Volume: 94, Issue:1 Topics: Acute Disease; Administration, Oral; Anti-Infective Agents; Aza Compounds; Bacterial Infections; Bronchitis; Chronic Disease; Double-Blind Method; Female; Fluoroquinolones; Humans; Male; Middle Aged; Moxifloxacin; Quinolines; Treatment Outcome	2000
A comparison of the safety and efficacy of moxifloxacin (BAY 12-8039) and cefuroxime axetil in the treatment of acute bacterial sinusitis in adults. The Sinusitis Study Group. Respiratory medicine, 2000, Volume: 94, Issue:4 Topics: Acute Disease; Adult; Anti-Infective Agents; Aza Compounds; Bacterial Infections; Cefuroxime; Cephalosporins; Double-Blind Method; Drug Evaluation; Female; Fluoroquinolones; Humans; Male; Middle Aged; Moxifloxacin; Prospective Studies; Quinolines; Sinusitis	2000
The safety and efficacy of short course (5-day) moxifloxacin vs. azithromycin in the treatment of patients with acute exacerbation of chronic bronchitis. Respiratory medicine, 2000, Volume: 94, Issue:11 Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Azithromycin; Bacterial Infections; Bronchitis; Chronic Disease; Double-Blind Method; Female; Fluoroquinolones; Humans; Male; Middle Aged; Moxifloxacin; Multicenter Studies as Topic; Prospective Studies; Quinolines	2000

Other Studies

34 other study(ies) available for moxifloxacin and Bacterial Disease

Article	Year
In vitro and in vivo activities of LCB01-0371, a new oxazolidinone. Antimicrobial agents and chemotherapy, 2010, Volume: 54, Issue:12 Topics: Acetamides; Animals; Anti-Bacterial Agents; Bacterial Infections; Gram-Positive Bacteria; Linezolid; Male; Mice; Mice, Inbred ICR; Oxazolidinones; Staphylococcus aureus; Vancomycin	2010
Synthesis and evaluation of anti-tubercular and antibacterial activities of new 4-(2,6-dichlorobenzyloxy)phenyl thiazole, oxazole and imidazole derivatives. Part 2. European journal of medicinal chemistry, 2012, Volume: 49 Topics: Anti-Bacterial Agents; Antitubercular Agents; Bacteria; Bacterial Infections; Humans; Imidazoles; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Oxazoles; Thiazoles; Tuberculosis	2012
Development of a Dual-Acting Antibacterial Agent (TNP-2092) for the Treatment of Persistent Bacterial Infections. Journal of medicinal chemistry, 2016, 07-28, Volume: 59, Issue:14 Topics: Anti-Bacterial Agents; Bacterial Infections; Dose-Response Relationship, Drug; Microbial Sensitivity Tests; Molecular Structure; Rifamycins; Staphylococcus aureus; Structure-Activity Relationship	2016
Novel C-7 carbon substituted fourth generation fluoroquinolones targeting N. Gonorrhoeae infections. Bioorganic & medicinal chemistry letters, 2020, 10-15, Volume: 30, Issue:20 Topics: Anti-Bacterial Agents; Bacterial Infections; Carbon; Dose-Response Relationship, Drug; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Molecular Structure; Neisseria gonorrhoeae; Structure-Activity Relationship	2020
Different breakpoints interpretation yielded distinct resistance rates to moxifloxacin of clinically significant anaerobic bacteria. Anaerobe, 2021, Volume: 72 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacteria, Anaerobic; Bacterial Infections; Bacterial Typing Techniques; Child; Child, Preschool; Drug Resistance, Bacterial; Female; Humans; Infant; Male; Microbial Sensitivity Tests; Middle Aged; Moxifloxacin; Young Adult	2021
Moxifloxacin releasing intraocular implant based on a cross-linked hyaluronic acid membrane. Scientific reports, 2021, 12-16, Volume: 11, Issue:1 Topics: Animals; Anti-Bacterial Agents; Bacterial Infections; Cataract Extraction; Drug Liberation; Drug Resistance, Bacterial; Hyaluronic Acid; Infusion Pumps, Implantable; Moxifloxacin; Postoperative Complications; Pseudomonas aeruginosa; Rabbits; Rats; Staphylococcus aureus	2021
Infection Rates Following Hepatic Embolotherapy in Patients with Prior Biliary Interventions: Comparison of Single-Drug Moxifloxacin and Multidrug Antibiotic Prophylaxis. Journal of vascular and interventional radiology : JVIR, 2021, Volume: 32, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Antibiotic Prophylaxis; Bacterial Infections; Biliary Tract Surgical Procedures; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Drug Therapy, Combination; Female; Humans; Incidence; Liver Neoplasms; Male; Middle Aged; Moxifloxacin; Radiopharmaceuticals; Retrospective Studies; Risk Factors; Time Factors; Treatment Outcome	2021
Safety and Tolerability of Moxifloxacin in Children. Journal of the Pediatric Infectious Diseases Society, 2018, Aug-17, Volume: 7, Issue:3 Topics: Administration, Intravenous; Administration, Oral; Adolescent; Alanine Transaminase; Anti-Bacterial Agents; Aspartate Aminotransferases; Bacterial Infections; Bilirubin; Blood Cell Count; Child; Child, Preschool; Drug Administration Schedule; Female; Fluoroquinolones; Humans; Infant; Long QT Syndrome; Male; Moxifloxacin; Neutropenia; Retrospective Studies; Seizures	2018
Moxifloxacin in Chronic Obstructive Pulmonary Disease: Pharmacokinetics and Penetration into Bronchial Secretions in Ward and Intensive Care Unit Patients. Antimicrobial agents and chemotherapy, 2019, Volume: 63, Issue:3 Topics: Aged; Anti-Bacterial Agents; Bacterial Infections; Critical Care; Disease Progression; Female; Humans; Intensive Care Units; Male; Microbial Sensitivity Tests; Moxifloxacin; Prospective Studies; Pulmonary Disease, Chronic Obstructive	2019
Design, synthesis and antibacterial activity evaluation of moxifloxacin-amide-1,2,3-triazole-isatin hybrids. Bioorganic chemistry, 2019, Volume: 91 Topics: Anti-Bacterial Agents; Bacteria; Bacterial Infections; Drug Design; Humans; Isatin; Molecular Docking Simulation; Molecular Structure; Moxifloxacin; Structure-Activity Relationship; Triazoles	2019
Effect of prophylactic antibiotics on polyacrylamide gel safety in facial augmentation. Journal of drugs in dermatology : JDD, 2014, Volume: 13, Issue:5 Topics: Acrylic Resins; Adolescent; Adult; Aged; Anti-Bacterial Agents; Antibiotic Prophylaxis; Azithromycin; Bacterial Infections; Biofilms; Cosmetic Techniques; Face; Female; Fluoroquinolones; Humans; Incidence; Inflammation; Injections; Male; Middle Aged; Moxifloxacin; Retrospective Studies; Young Adult	2014
Tissue penetration of moxifloxacin into human gallbladder wall in patients with biliary tract infections. The Journal of antimicrobial chemotherapy, 2009, Volume: 64, Issue:5 Topics: Adult; Aged; Anti-Bacterial Agents; Aza Compounds; Bacterial Infections; Biliary Tract Diseases; Cholecystitis; Chromatography, High Pressure Liquid; Female; Fluoroquinolones; Gallbladder; Humans; Infusions, Intravenous; Male; Middle Aged; Moxifloxacin; Quinolines; Serum; Time Factors; Young Adult	2009
In vitro activities of moxifloxacin and tigecycline against bacterial isolates associated with intraabdominal infections at a medical center in Taiwan, 2001-2006. European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2009, Volume: 28, Issue:12 Topics: Anti-Bacterial Agents; Aza Compounds; Bacteria; Bacterial Infections; Bacterial Proteins; beta-Lactamases; Community-Acquired Infections; Cross Infection; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Minocycline; Moxifloxacin; Peritonitis; Quinolines; Taiwan; Tigecycline	2009
Pharmacokinetics, plasma protein binding and bioavailability of moxifloxacin in Muscovy ducks after different routes of administration. Research in veterinary science, 2010, Volume: 88, Issue:3 Topics: Administration, Oral; Animals; Anti-Infective Agents; Antitubercular Agents; Aza Compounds; Bacterial Infections; Biological Availability; Bird Diseases; Blood Proteins; Chromatography, High Pressure Liquid; Ducks; Fluoroquinolones; Half-Life; Injections, Intravenous; Metabolic Clearance Rate; Moxifloxacin; Protein Binding; Quinolines; Tissue Distribution	2010
[Highlights of the Congress of the National Infectious Disease Medicine Days 2010]. Medecine et maladies infectieuses, 2011, Volume: 41, Issue:1 Suppl 1 Topics: Anti-Bacterial Agents; Arthritis, Infectious; Aza Compounds; Bacterial Infections; beta-Lactamases; Chemical and Drug Induced Liver Injury; Clinical Trials as Topic; Drug Resistance, Microbial; Fluoroquinolones; France; Humans; Infectious Disease Medicine; Moxifloxacin; Multicenter Studies as Topic; Osteitis; Prosthesis-Related Infections; Quinolines; Societies, Medical; Treatment Outcome	2011
Intravenous moxifloxacin. Even more harmful than the oral form. Prescrire international, 2011, Volume: 20, Issue:117 Topics: Administration, Oral; Anti-Bacterial Agents; Aza Compounds; Bacterial Infections; Fluoroquinolones; Humans; Infusions, Intravenous; Moxifloxacin; Quinolines	2011
Moxifloxacin-Gelrite in situ ophthalmic gelling system against photodynamic therapy for treatment of bacterial corneal inflammation. Archives of pharmacal research, 2011, Volume: 34, Issue:10 Topics: Adhesiveness; Animals; Anti-Bacterial Agents; Aqueous Humor; Area Under Curve; Aza Compounds; Bacterial Infections; Bacterial Load; Chemistry, Pharmaceutical; Cornea; Corneal Diseases; Escherichia coli; Excipients; Fluoroquinolones; Gels; Keratitis; Light; Male; Microbial Sensitivity Tests; Moxifloxacin; Mucous Membrane; Ophthalmic Solutions; Osmotic Pressure; Photochemotherapy; Polysaccharides, Bacterial; Quinolines; Rabbits; Reference Standards; Spectrometry, Fluorescence; Staphylococcus aureus; Viscosity	2011
Relationship of in vitro susceptibility to moxifloxacin and in vivo clinical outcome in bacterial keratitis. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2012, Volume: 54, Issue:10 Topics: Anti-Bacterial Agents; Aza Compounds; Bacteria; Bacterial Infections; Corneal Ulcer; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Moxifloxacin; Quinolines; Treatment Outcome	2012
Antibiotics in acute exacerbations of COPD: the good, the bad and the ugly. The European respiratory journal, 2012, Volume: 40, Issue:1 Topics: Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Aza Compounds; Bacterial Infections; Female; Fluoroquinolones; Humans; Male; Moxifloxacin; Pulmonary Disease, Chronic Obstructive; Quinolines	2012
Antianaerobic activity of moxifloxacin compared with that of ofloxacin, ciprofloxacin, clindamycin, metronidazole and beta-lactams. International journal of antimicrobial agents, 2002, Volume: 20, Issue:5 Topics: Anaerobiosis; Anti-Bacterial Agents; Aza Compounds; Bacterial Infections; beta-Lactams; Ciprofloxacin; Clindamycin; Fluoroquinolones; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Metronidazole; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Quinolines	2002
[Respiratory tract infections. Increasingly more established antibiotics fail]. MMW Fortschritte der Medizin, 2002, Oct-17, Volume: 144, Issue:42 Topics: Anti-Infective Agents; Aza Compounds; Bacterial Infections; Drug Resistance, Multiple; Fluoroquinolones; Humans; Moxifloxacin; Quinolines; Respiratory Tract Infections; Treatment Outcome	2002
The penetration of moxifloxacin into the pancreas of male rats in experimental acute necrotizing pancreatitis. Chemotherapy, 2003, Volume: 49, Issue:4 Topics: Animals; Anti-Infective Agents; Aza Compounds; Bacterial Infections; Fluoroquinolones; Male; Moxifloxacin; Pancreas; Pancreatitis, Acute Necrotizing; Quinolines; Rats; Rats, Wistar; Tissue Distribution	2003
In vitro antimicrobial activity of moxifloxacin compared to other quinolones against recent clinical bacterial isolates from hospitalized and community-based cancer patients. Diagnostic microbiology and infectious disease, 2003, Volume: 47, Issue:2 Topics: Anti-Infective Agents; Aza Compounds; Bacterial Infections; Drug Resistance, Bacterial; Fluoroquinolones; Gram-Negative Bacteria; Gram-Positive Bacteria; Hospitalization; Humans; Microbial Sensitivity Tests; Moxifloxacin; Neoplasms; Quinolines	2003
Preventive antibacterial treatment improves the general medical and neurological outcome in a mouse model of stroke. Stroke, 2004, Volume: 35, Issue:1 Topics: Animals; Antibiotic Prophylaxis; Aza Compounds; Bacterial Infections; Body Weight; Disease Models, Animal; Dose-Response Relationship, Drug; Escherichia coli Infections; Fever; Fluoroquinolones; Gram-Positive Bacterial Infections; Hypothermia; Immune Tolerance; Male; Mice; Mice, Inbred Strains; Moxifloxacin; Opportunistic Infections; Pneumonia, Bacterial; Quinolines; Sepsis; Stroke; Survival Rate; Treatment Outcome	2004
In vitro activities of moxifloxacin against 900 aerobic and anaerobic surgical isolates from patients with intra-abdominal and diabetic foot infections. Antimicrobial agents and chemotherapy, 2004, Volume: 48, Issue:3 Topics: Abdomen; Anti-Infective Agents; Aza Compounds; Bacteria, Aerobic; Bacteria, Anaerobic; Bacterial Infections; Diabetic Foot; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Moxifloxacin; Quinolines	2004
[Gigantic study planned. 100,000 patients with COPD test general practice antibiotic]. MMW Fortschritte der Medizin, 2004, Mar-04, Volume: 146, Issue:10 Topics: Anti-Bacterial Agents; Aza Compounds; Bacterial Infections; Clinical Trials as Topic; Drug Administration Schedule; Fluoroquinolones; Humans; Moxifloxacin; Multicenter Studies as Topic; Pulmonary Disease, Chronic Obstructive; Quinolines; Secondary Prevention; Treatment Outcome	2004
Pharmacokinetics of moxifloxacin in patients undergoing continuous venovenous haemodiafiltration. The Journal of antimicrobial chemotherapy, 2004, Volume: 54, Issue:4 Topics: Acute Kidney Injury; Adult; Aged; Anti-Bacterial Agents; Aza Compounds; Bacterial Infections; Chromatography, High Pressure Liquid; Drug Administration Schedule; Female; Fluoroquinolones; Hemodiafiltration; Hemodialysis Solutions; Humans; Injections, Intravenous; Male; Metabolic Clearance Rate; Middle Aged; Moxifloxacin; Quinolines; Severity of Illness Index	2004
[Moxifloxacin in general practice. Economical concept]. MMW Fortschritte der Medizin, 2004, Nov-11, Volume: 146, Issue:46 Topics: Aza Compounds; Bacterial Infections; Clinical Trials as Topic; Cost Savings; Fluoroquinolones; Humans; Moxifloxacin; Quinolines; Respiratory Tract Infections; Treatment Outcome	2004
Comparative in vitro antimicrobial activity of a novel quinolone, garenoxacin, against aerobic and anaerobic microbial isolates recovered from general, vascular, cardiothoracic and otolaryngologic surgical patients. The Journal of antimicrobial chemotherapy, 2005, Volume: 56, Issue:5 Topics: Anti-Bacterial Agents; Aza Compounds; Bacteria, Aerobic; Bacteria, Anaerobic; Bacterial Infections; Fluoroquinolones; Humans; Imipenem; Metronidazole; Microbial Sensitivity Tests; Moxifloxacin; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Quinolines	2005
Controversies in antibiotic choices for odontogenic infections. Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics, 2006, Volume: 101, Issue:6 Topics: Anti-Bacterial Agents; Aza Compounds; Bacteria, Anaerobic; Bacterial Infections; Clindamycin; Drug Resistance, Bacterial; Fluoroquinolones; Focal Infection, Dental; Humans; Moxifloxacin; Quinolines; Spain; Streptococcal Infections; Viridans Streptococci	2006
Comparison of the in vitro activities of Bay 12-8039, a new quinolone, and other antimicrobials against clinically important anaerobes. Antimicrobial agents and chemotherapy, 1997, Volume: 41, Issue:3 Topics: Anti-Infective Agents; Aza Compounds; Bacteria, Anaerobic; Bacterial Infections; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Moxifloxacin; Quinolines; Quinolones	1997
Comparative activity of moxifloxacin in vitro against obligately anaerobic bacteria. European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2000, Volume: 19, Issue:3 Topics: Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Bacteria, Anaerobic; Bacterial Infections; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Moxifloxacin; Quinolines	2000
In vitro activity of moxifloxacin against common clinical bacterial isolates in Taiwan. Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi, 2001, Volume: 34, Issue:3 Topics: Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Bacterial Infections; Fluoroquinolones; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Microbial Sensitivity Tests; Moxifloxacin; Quinolines	2001
Susceptibility to moxifloxacin and other antimicrobial agents of major pathogens responsible for community acquired respiratory tract infection in Poland. International journal of antimicrobial agents, 2002, Volume: 19, Issue:1 Topics: Anti-Bacterial Agents; Aza Compounds; Bacterial Infections; Community-Acquired Infections; Fluoroquinolones; Haemophilus influenzae; Humans; In Vitro Techniques; Microbial Sensitivity Tests; Moraxella catarrhalis; Moxifloxacin; Penicillin Resistance; Poland; Quinolines; Respiratory Tract Infections; Streptococcus pneumoniae; Streptococcus pyogenes	2002